"We're looking for targets, and we even have to broaden our range of potential acquisition targets in view of royalties from our American sales partners, AbbVie," Orbán told the paper.

"In the past, we've focused more on acquiring products or portfolios and less on companies, and especially not infrastructure. Now we have to think in terms of a slightly broader range. At the moment, the management is discussing in what direction that range should be broadened," he said.